Prosecution Insights
Last updated: August 17, 2026

Examiner: RAHMANI, NILOOFAR

Tech Center 1600 • Art Units: 1621 1625 1634 1691

This examiner grants 78% of resolved cases

Performance Statistics

77.5%
Allow Rate
+17.5% vs TC avg
1,152
Total Applications
-3.1%
Interview Lift
722
Avg Prosecution Days
Based on 1138 resolved cases, 2023–2026

Rejection Statute Breakdown

2.7%
§101 Eligibility
27.8%
§102 Novelty
14.0%
§103 Obviousness
39.1%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18291630 PHOSPHATE PRODRUGS OF CANNABINOIDS Non-Final OA Emory University
18674715 SMALL MOLECULE INHIBITORS OF INTERLEUKIN-4 Non-Final OA Massachusetts Institute of Technology
18566008 COMPOSITIONS OF CLOFAZIMINE AND AMIKACIN FOR PULMONARY ADMINISTRATION IN THE TREATMENT OF RESPIRATORY DISEASES Final Rejection BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
18722233 COMBINATION OF AN A2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A NOREPINEPHRINE REUPTAKE INHIBITOR FOR THE TREATMENT OF SLEEP APNEA Non-Final OA BAYER AKTIENGESELLSCHAFT
17762325 TREATMENT AND PREVENTION OF AGING RELATED-DISEASE AND/OR AGING BY THE INHIBITION OF SPHINGOLIPIDS Final Rejection ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month